Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.45 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CTSV | O60911 | 4/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803081 | 0.88 | DPP4 (0.58) | DPP4CTSSCTSVCTSKCTSL | |
| SCHEMBL6796926 | 0.86 | DPP4 (0.45) | DPP4CTSSCTSVCTSKCTSL | |
| SCHEMBL5098324 | 0.85 | DPP4 (0.58) | DPP4CTSSCTSVCTSKCTSL | |
| SCHEMBL5092222 | 0.85 | DPP4 (0.52) | DPP4CTSSCTSVCTSKCTSL | |
| SCHEMBL6803957 | 0.85 | DPP4 (0.46) | DPP4CTSSCTSVCTSKCTSL | |
| SCHEMBL6803733 | 0.84 | DPP4 (0.53) | DPP4CTSSCTSVCTSKCTSL | |
| SCHEMBL6798993 | 0.84 | DPP4 (0.53) | DPP4CTSSCTSVCTSKCTSL | |
| SCHEMBL4564702 | 0.84 | DPP4 (0.57) | DPP4CTSSCTSVCTSKCTSL | |
| SCHEMBL5139736 | 0.83 | CTSS (0.46) | DPP4CTSSCTSVCTSKCTSL | |
| SCHEMBL6801204 | 0.82 | DPP4 (0.54) | DPP4CTSSCTSVCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | DPP4 670/4885CTSS 39/4885CTSV 27/4885 |
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | CPN1, CTRL, CPA1 | DPP4 651/4885CTSS 21/4885CTSV 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.